Gonadorelin Guide: Synthetic GnRH for Hormone Regulation

Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) with a molecular weight of approximately 1,182 Da that the hypothalamus produces to control reproductive hormone output. When it reaches the anterior pituitary via the hypothalamic-pituitary portal circulation, it stimulates gonadotroph cells to synthesise and release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins then act on the gonads to drive testosterone production, oestrogen production and spermatogenesis or oogenesis.

Unlike every other compound in the growth hormone secretagogues cluster, gonadorelin does not act on the GH axis at all. It has no affinity for GHS-R1a (the ghrelin receptor), does not release growth hormone from somatotrophs, and has no role in IGF-1 signalling. It sits in this cluster because it is sometimes grouped with GH secretagogues in compounding pharmacy catalogues and peptide-market discussions, but its biology is entirely distinct. Its axis is the hypothalamic-pituitary-gonadal (HPG) axis, not the GH/IGF-1 axis.

From Nobel Prize to Clinical Tool

The existence of GnRH was hypothesised from the 1950s, but its structure was not established until Roger Guillemin and Andrew Schally, working in separate laboratories, independently isolated and characterised it from animal hypothalami in the late 1960s and early 1970s. Their achievement – extracting sufficient quantities of releasing hormones from tens of thousands of hypothalamic tissue fragments – earned them the 1977 Nobel Prize in Physiology or Medicine, shared with Rosalyn Yalow “for discoveries concerning the peptide hormone production of the brain.” Guillemin, who continued working at the Salk Institute until his retirement, died in February 2024 at the age of 100.

Synthetic gonadorelin was developed as a clinical tool within years of the structural discovery. The FDA approved two gonadorelin products: Factrel (gonadorelin hydrochloride injection, manufactured by Wyeth) for diagnostic testing of pituitary-gonadotroph function, and Lutrepulse (gonadorelin acetate, delivered via subcutaneous pump) for the induction of ovulation in women with primary hypothalamic amenorrhea. Both products were later commercially withdrawn by their manufacturers – not by the FDA, and not for safety or efficacy reasons. No replacement approved product has been brought to market.

The bottom line: Gonadorelin is the synthetic form of a Nobel Prize-winning hormone discovery that acts on the reproductive axis, not the growth hormone axis, and has a prior FDA approval history that no other peptide in this cluster can match.

Gonadorelin binds to the GnRH receptor (GnRHR), a G-protein-coupled receptor on the surface of pituitary gonadotroph cells. Receptor activation triggers inositol phosphate signalling and calcium mobilisation, leading to the release of pre-formed LH granules (the faster response) and upregulation of both LH and FSH synthesis (the slower response). In the body, this process is controlled by pulsatile secretion from hypothalamic GnRH neurons: each pulse of GnRH produces a corresponding pulse of LH.

The Pulsatile Paradox

Gonadorelin’s most clinically important property is also its most counterintuitive: the same molecule that stimulates LH and FSH release when given in pulses will suppress them when given continuously. Pulsatile GnRH exposure maintains receptor sensitivity and drives normal gonadotropin output. Continuous or high-frequency exposure desensitises and downregulates the GnRH receptor, shutting down gonadotropin release entirely. This is not a theoretical concern – it is the pharmacological basis for an entire class of drugs. GnRH agonists such as leuprolide and triptorelin exploit this desensitisation effect to achieve chemical castration in prostate cancer and to suppress puberty in central precocious puberty.

The practical consequence is that dosing frequency matters fundamentally. The Lutrepulse pump was designed to deliver pulses every 90 to 120 minutes, mimicking the physiological rhythm. A single daily bolus injection does not replicate this pulsatile pattern, and whether subcutaneous bolus dosing at typical compounding-pharmacy frequencies (once or twice daily) generates enough receptor stimulation to maintain meaningful LH output – without crossing into desensitisation territory – is not well-characterised in controlled human trials as of mid-2026.

The bottom line: Gonadorelin stimulates reproductive hormones when pulsed but suppresses them when delivered continuously – making dosing pattern as important as dose size.

Gonadorelin’s evidence base divides sharply into two eras: the well-established pulsatile-pump literature for diagnosed hypogonadotropic conditions, and the much thinner evidence for the compounded subcutaneous-bolus use that dominates current clinical practice.

Indication / Context	Evidence Tier	Key Finding
Pulsatile pump for congenital hypogonadotropic hypogonadism (CHH)	FDA-approved indication (Lutrepulse); multiple RCTs	Effective at restoring pulsatile LH/FSH, inducing spermatogenesis and ovulation in CHH
Diagnostic (GnRH stimulation test)	FDA-approved indication (Factrel); clinical standard	Single IV bolus produces measurable LH/FSH spike to assess pituitary reserve. Used in evaluation of central precocious puberty and GnRH agonist suppression
TRT adjunct (subcutaneous bolus) for testicular function preservation	Extrapolation from CHH data; limited direct trials	Community and clinic experience suggests subcutaneous bolus may reduce testicular atrophy during TRT, but no controlled trials have directly compared compounded gonadorelin vs HCG for this specific use
Hochu et al. 2025 (Transl Androl Urol)	Narrative review	Reviewed options for preserving spermatogenesis during TRT after the HCG supply disruption; noted gonadorelin adoption but flagged the limited direct evidence base

The HCG Replacement Question

The event that transformed gonadorelin from a niche diagnostic tool into one of the most widely compounded peptides in the US was the March 2020 biologics reclassification. Under the Biologics Price Competition and Innovation Act of 2009 (BPCIA), HCG was reclassified as a biologic effective 23 March 2020, meaning compounding pharmacies could no longer produce it under standard 503A or 503B frameworks. Because compounded HCG had been the standard of care for preserving testicular function and fertility during testosterone replacement therapy, clinicians urgently needed an alternative. Gonadorelin filled that gap.

The pharmacological logic is sound in principle: gonadorelin stimulates LH release from the pituitary, and LH then drives testicular testosterone production and spermatogenesis, achieving a similar downstream result to HCG (which mimics LH directly at the gonad). But the two compounds are not interchangeable. HCG bypasses the pituitary entirely and acts directly on testicular LH receptors with a long half-life (24 to 36 hours), allowing dosing two to three times per week. Gonadorelin acts upstream at the pituitary, requires an intact and responsive pituitary that has not been fully suppressed by exogenous testosterone, and has a half-life measured in minutes rather than hours.

Whether subcutaneous gonadorelin boluses at once or twice-daily compounding-pharmacy frequencies generate enough LH stimulation to meaningfully maintain testicular function during TRT – compared with the robust evidence base behind HCG – has not been settled in controlled trials. A 2025 review by Hochu and colleagues in Translational Andrology and Urology acknowledged gonadorelin’s widespread adoption but noted the limited direct evidence. One small, non-randomised open-label study has compared the two, but the field lacks a properly powered RCT.

The bottom line: Gonadorelin is pharmacologically rational as an HCG alternative, but the direct evidence supporting compounded subcutaneous bolus dosing for TRT-adjunct use remains limited as of mid-2026.

The GnRH Stimulation Test

The oldest and best-validated clinical use of gonadorelin is diagnostic: a single intravenous bolus is administered to evaluate whether the pituitary can mount a normal gonadotropin response. This GnRH stimulation test remains a standard-of-care tool in paediatric endocrinology for evaluating central precocious puberty and in adult endocrinology for differentiating hypothalamic from pituitary causes of hypogonadism. In published clinical protocols (including the original Factrel prescribing information and paediatric endocrinology guidelines), blood is sampled at defined intervals after a weight-based intravenous bolus, and a suppressed LH peak at or below a defined threshold confirms adequate GnRH-agonist suppression in children being treated for precocious puberty.

This diagnostic use is directly relevant to the broader gonadorelin story because it illustrates two key points. First, even a single bolus produces a measurable, reproducible pituitary response – confirming that the compound works. Second, the test depends on pulsatile naivety: the pituitary must not already be desensitised by prior continuous GnRH exposure. In patients already receiving depot GnRH agonists (leuprolide, triptorelin), the test is used precisely to confirm that desensitisation has occurred. This reinforces the paradoxical-dosing principle described above.

Where Gonadorelin Sits Among TRT Adjuncts

Gonadorelin is not the only compound prescribed alongside TRT to mitigate HPG-axis suppression. Enclomiphene (the trans-isomer of clomiphene) is an oestrogen-receptor antagonist that blocks negative feedback at the hypothalamus and pituitary, thereby increasing endogenous GnRH, LH and FSH output. It acts upstream of gonadorelin in the axis and has the advantage of oral dosing with a half-life of approximately 10 hours. Clinical data supporting enclomiphene for testosterone maintenance are more extensive than for compounded gonadorelin, including published trials demonstrating sustained LH, testosterone and spermatogenesis in hypogonadal men. However, enclomiphene’s FDA approval status is also complex (an NDA has been filed but not approved as of mid-2026), and access is through compounding pharmacies.

The pharmacological distinction matters: enclomiphene works by disinhibiting the patient’s own GnRH secretion, so its efficacy depends on intact hypothalamic function. Gonadorelin replaces the GnRH signal directly at the pituitary. HCG bypasses the pituitary entirely and acts at the gonad. In theory, these three mechanisms could even be complementary, but no controlled trial has compared them head-to-head in TRT-suppressed men, and the optimal adjunct strategy remains a matter of clinical judgement rather than high-quality evidence.

Gonadorelin occupies a distinctly better regulatory position than most peptides discussed on this site, owing to its prior FDA approvals and Category 1 listing.

Jurisdiction	Status	Detail
US (FDA)	Formerly approved (Factrel, Lutrepulse); commercially withdrawn	No active NDA or ANDA. Gonadorelin acetate added to 503B Category 1 list. Compounding available through licensed 503A and 503B pharmacies with valid prescription. Withdrawal was by manufacturer (commercial reasons), not by FDA enforcement
UK (MHRA)	No current marketing authorisation as standalone product	GnRH analogues available via NHS for approved indications; synthetic gonadorelin itself not separately licensed in the UK
Australia (TGA)	Prescription only	Available under medical supervision. Access via SAS or Authorised Prescriber pathway for off-label use
WADA	Prohibited at all times (S2)	GnRH and its analogs listed under S2 peptide hormones and growth factors

The critical regulatory distinction is that gonadorelin was a component of FDA-approved drugs (Factrel and Lutrepulse). Under 21 U.S.C. 353a(b)(1)(A)(ii), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding even without a separate USP monograph or 503A bulks list entry. Gonadorelin acetate was also explicitly added to the 503B Category 1 list. This is a fundamentally different regulatory footing from compounds like GHRP-6, which has no prior approval, no USP monograph and sits outside the interim policy entirely.

For how the FDA’s category system and compounding pathways work, see our guide to FDA Category 1 vs Category 2. For how individual countries regulate peptides more broadly, see our guides for the US, the UK and Australia.

The bottom line: Gonadorelin is the only compound in this cluster with prior FDA approval and Category 1 status, giving it the strongest regulatory foundation of any GH-secretagogue-adjacent peptide.

Gonadorelin’s safety profile in the approved Factrel and Lutrepulse formulations was well characterised and generally favourable, with adverse events that were mostly mild and self-limiting.

Injection-site reactions (redness, swelling, mild pain) were the most commonly reported events in clinical use. Headache, nausea and abdominal discomfort occurred at low frequency. Flushing was reported in some patients after intravenous administration. Rare cases of hypersensitivity reactions including bronchospasm were documented in the Factrel prescribing information, and anaphylaxis was listed as a possibility. Antibody formation was observed in some patients on long-term pulsatile pump therapy (Lutrepulse), though the clinical significance was uncertain.

The most significant safety consideration for compounded subcutaneous bolus use is the risk of paradoxical suppression. If dosing frequency is too high or if continuous-release formulations are inadvertently used, gonadorelin will desensitise the GnRH receptor and suppress LH/FSH output – the opposite of the intended effect. This is not a theoretical risk; it is the mechanistic basis for an entire therapeutic class (GnRH agonist depot injections used in prostate cancer and endometriosis). Users and prescribers working with compounded gonadorelin must understand that more frequent dosing does not necessarily mean more LH output.

A separate concern applies to men using gonadorelin as a TRT adjunct. Exogenous testosterone suppresses hypothalamic GnRH output through negative feedback. Whether exogenous gonadorelin can meaningfully override this pituitary suppression, or whether the pituitary gonadotrophs are themselves downregulated by the lack of endogenous GnRH pulses, is not established in controlled trials. The possibility that compounded gonadorelin produces less intratesticular testosterone than expected in a TRT-suppressed context is a real gap in the evidence.

Gonadorelin is also contraindicated in patients with known GnRH-dependent tumours (such as GnRH-receptor-positive pituitary adenomas) or a history of hypersensitivity to GnRH or its analogues. Women who may be pregnant should not use it.

The Compounding Quality Variable

Because no FDA-approved gonadorelin product is currently on the market, all US supply comes through compounding pharmacies. This introduces a quality variable that did not exist when Factrel and Lutrepulse were manufactured under full FDA oversight. Compounded peptide products are not subject to the same manufacturing standards, batch-release testing or post-market surveillance as approved drugs. Independent testing of compounded peptide products has repeatedly found inconsistencies between labelled and actual content, including incorrect potency and the presence of impurities or degradation products.

For a peptide whose biological effect is exquisitely sensitive to concentration and dosing frequency – where too much can paradoxically suppress the very hormones it is meant to stimulate – the consistency of the compounded product is not a minor detail. Patients obtaining compounded gonadorelin through licensed 503A or 503B pharmacies with valid prescriptions have materially different risk profiles from those obtaining products from unregulated online sources, but neither route provides the quality assurance of an FDA-approved product. A third-party certificate of analysis should accompany any compounded peptide, and our guide to reading a COA explains what to look for.

The bottom line: Gonadorelin has a favourable safety record in its approved formulations, but the risk of paradoxical suppression from incorrect dosing frequency is clinically significant and poorly understood in current compounding-pharmacy use.

Gonadorelin acts on the GnRH receptor on pituitary gonadotrophs, releasing LH and FSH into the HPG axis. It does not bind GHS-R1a (the ghrelin receptor), does not act on somatotrophs, does not release growth hormone, and has no effect on IGF-1. Its inclusion in the growth hormone secretagogues cluster on this site is purely organisational – it appears alongside GH secretagogues in many compounding pharmacy product lists and in peptide-market discussions, and readers searching for it may arrive via those associations.

Every other compound in this cluster – from sermorelin and CJC-1295 (GHRH-receptor agonists) to ipamorelin, hexarelin and GHRP-2 (ghrelin-receptor agonists) to MK-677 (an oral ghrelin-mimetic) – targets the somatotroph axis. Gonadorelin targets the gonadotroph axis. These are fundamentally different endocrine pathways, and confusing one for the other leads to incorrect expectations about what gonadorelin can and cannot do.

For current regulatory developments affecting all peptides in this space, see the RFK peptide reclassification tracker.

Is gonadorelin the same thing as GnRH?

Synthetic gonadorelin is identical in amino acid sequence to endogenous GnRH. It has the same ten-amino-acid structure (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and binds the same pituitary receptor. However, endogenous GnRH is released in precisely timed pulses from hypothalamic neurons, and its biological effect depends on that pulsatile pattern. Injecting gonadorelin subcutaneously once or twice daily does not replicate the natural pulse frequency, which is typically one pulse every 60 to 120 minutes.

Why did gonadorelin replace HCG in TRT protocols?

HCG was reclassified as a biologic under the BPCIA effective March 2020, which meant 503A and 503B compounding pharmacies could no longer produce it. Because compounded HCG had been the standard adjunct for preserving testicular function during TRT, clinicians needed an alternative that could be legally compounded. Gonadorelin, with its prior FDA approval history and Category 1 status, was the most accessible option. The shift was driven by a regulatory supply disruption, not by clinical trial evidence demonstrating that gonadorelin is equivalent to HCG for this use.

Can continuous dosing of gonadorelin shut down testosterone production?

Yes, in principle. Continuous or excessively frequent GnRH-receptor stimulation causes receptor desensitisation and downregulation, suppressing LH and FSH output and therefore gonadal steroid production. This is the deliberate pharmacological mechanism of depot GnRH agonists used in prostate cancer. Whether typical compounding-pharmacy dosing frequencies (once or twice daily subcutaneous injections) produce continuous enough receptor exposure to trigger meaningful suppression is not established, but the risk is physiologically real and is the reason that the approved Lutrepulse product used a pump delivering pulses every 90 to 120 minutes.

Does gonadorelin affect growth hormone levels?

No. Gonadorelin acts on the GnRH receptor on pituitary gonadotrophs, stimulating LH and FSH release. It does not bind the ghrelin receptor (GHS-R1a), does not act on somatotroph cells, and has no direct effect on growth hormone or IGF-1. It is categorically different from compounds like sermorelin, ipamorelin or GHRP-6, all of which target the GH axis through either the GHRH receptor or the ghrelin receptor.

What happened to Factrel and Lutrepulse?

Both products were commercially withdrawn by their manufacturers – Factrel by Wyeth (later acquired by Pfizer) and Lutrepulse by its manufacturer. The withdrawals were voluntary commercial decisions, not FDA enforcement actions based on safety or efficacy concerns. No equivalent approved product has been brought to market to replace either one, which is why current US access to gonadorelin is exclusively through licensed compounding pharmacies operating under section 503A or 503B.

Is gonadorelin banned in sport?

Yes. GnRH and its analogues are prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics). This includes gonadorelin, leuprolide, triptorelin and all other GnRH agonists and antagonists. The prohibition applies whether the compound is used to stimulate or suppress gonadotropin output. Athletes subject to WADA-code testing cannot use gonadorelin without a Therapeutic Use Exemption.

How does gonadorelin differ from GnRH antagonists like cetrorelix?

Gonadorelin is a GnRH agonist – it activates the GnRH receptor. GnRH antagonists like cetrorelix and degarelix block the receptor without activating it, producing immediate suppression of LH and FSH without the initial stimulatory flare that agonists cause. In clinical practice, antagonists are used when rapid and reliable gonadotropin suppression is needed (for example, in IVF protocols to prevent premature ovulation), while agonists are used when pulsatile stimulation of the HPG axis is the goal. The two classes achieve opposite effects despite targeting the same receptor.